Trethera Corporation Profile last edited on: 2/2/2024
CAGE: 7NJ74
UEI: QB66ZMAUF5P7
Business Identifier: Precise Targeting of Nucleotide Metabolism for the Treatment of Cancers and Autoimmune Diseases 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
13547 Ventura Boulevard Suite 363
Sherman Oaks, CA 91423
Sherman Oaks, CA 91423
| (323) 518-6901 |
| sshroyer@trethera.com |
| www.trethera.com |
Location: Single
Congr. District: 32
County: Los Angeles
Congr. District: 32
County: Los Angeles
Public Profile
Trethera is a biotechnology company that discovers and develops small molecules that control DNA replication and integrity.This approach is designed to overcome the limitations of single agent treatments and the associated risks of treatment failure and drug resistance. The combination therapy is addressing the alternative pathways of nucleotidebiosynthesis, namely the de novo and the salvage pathways, as well as the mechanisms that protect the cancer genome against DNA replication stress and damage. The combination therapy causes an imbalance in the supply and demand of nucleotides which is lethal to cancer cells and well-tolerated by normal tissues.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 1741779201 | 2 | NIH | $1,050,001 | |
| Project Title: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM) | ||||
| 2024 | 2 | NIH | $610,850 | |
| Project Title: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus | ||||
| 2024 | 2 | NIH | $601,607 | |
| Project Title: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM) | ||||
| 2024 | 2 | NIH | $2,046,376 | |
| Project Title: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types | ||||
| 2023 | 1 | NIH | $395,119 | |
| Project Title: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease | ||||
Key People / Management
Kenneth Schultz
Company News
There are no news available.
